|
Valoración de DCF de United Therapeutics Corporation (UTHR)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
United Therapeutics Corporation (UTHR) Bundle
Como inversor o analista, esta calculadora DCF [símbolo] (UTHR) es el recurso perfecto para una valoración precisa. Cargados con datos reales de United Therapeutics Corporation, puede ajustar fácilmente los pronósticos y observar los efectos en tiempo real.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,448.8 | 1,483.3 | 1,685.5 | 1,936.3 | 2,327.5 | 2,624.8 | 2,960.1 | 3,338.2 | 3,764.7 | 4,245.6 |
| Revenue Growth, % | 0 | 2.38 | 13.63 | 14.88 | 20.2 | 12.77 | 12.77 | 12.77 | 12.77 | 12.77 |
| EBITDA | -74.9 | 646.3 | 736.8 | 1,040.3 | 1,386.8 | 1,025.9 | 1,157.0 | 1,304.8 | 1,471.4 | 1,659.4 |
| EBITDA, % | -5.17 | 43.57 | 43.71 | 53.73 | 59.58 | 39.09 | 39.09 | 39.09 | 39.09 | 39.09 |
| Depreciation | 45.9 | 49.9 | 49.9 | 51.3 | 53.2 | 75.7 | 85.4 | 96.3 | 108.6 | 122.5 |
| Depreciation, % | 3.17 | 3.36 | 2.96 | 2.65 | 2.29 | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 |
| EBIT | -120.8 | 596.4 | 686.9 | 989.0 | 1,333.6 | 950.2 | 1,071.5 | 1,208.4 | 1,362.8 | 1,536.9 |
| EBIT, % | -8.34 | 40.21 | 40.75 | 51.08 | 57.3 | 36.2 | 36.2 | 36.2 | 36.2 | 36.2 |
| Total Cash | 2,253.4 | 2,984.6 | 3,580.6 | 4,154.9 | 2,994.1 | 2,624.8 | 2,960.1 | 3,338.2 | 3,764.7 | 4,245.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 151.4 | 157.4 | 198.7 | 220.4 | 278.9 | 295.1 | 332.8 | 375.3 | 423.3 | 477.3 |
| Account Receivables, % | 10.45 | 10.61 | 11.79 | 11.38 | 11.98 | 11.24 | 11.24 | 11.24 | 11.24 | 11.24 |
| Inventories | 93.4 | 86.5 | 93.8 | 102.0 | 111.8 | 146.5 | 165.3 | 186.4 | 210.2 | 237.0 |
| Inventories, % | 6.45 | 5.83 | 5.57 | 5.27 | 4.8 | 5.58 | 5.58 | 5.58 | 5.58 | 5.58 |
| Accounts Payable | 9.9 | 4.1 | 3.8 | 4.1 | 5.6 | 8.6 | 9.7 | 10.9 | 12.3 | 13.9 |
| Accounts Payable, % | 0.68332 | 0.27641 | 0.22545 | 0.21174 | 0.2406 | 0.32751 | 0.32751 | 0.32751 | 0.32751 | 0.32751 |
| Capital Expenditure | -83.7 | -59.3 | -120.8 | -138.8 | -230.4 | -178.5 | -201.3 | -227.1 | -256.1 | -288.8 |
| Capital Expenditure, % | -5.78 | -4 | -7.17 | -7.17 | -9.9 | -6.8 | -6.8 | -6.8 | -6.8 | -6.8 |
| Tax Rate, % | 22.72 | 22.72 | 22.72 | 22.72 | 22.72 | 22.72 | 22.72 | 22.72 | 22.72 | 22.72 |
| EBITAT | -76.5 | 480.6 | 550.3 | 756.7 | 1,030.6 | 718.0 | 809.7 | 913.1 | 1,029.8 | 1,161.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -349.2 | 466.3 | 430.5 | 639.6 | 786.6 | 567.2 | 638.4 | 720.0 | 812.0 | 915.7 |
| WACC, % | 7.03 | 7.09 | 7.09 | 7.07 | 7.08 | 7.07 | 7.07 | 7.07 | 7.07 | 7.07 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2,941.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 934 | |||||||||
| Terminal Value | 18,416 | |||||||||
| Present Terminal Value | 13,087 | |||||||||
| Enterprise Value | 16,028 | |||||||||
| Net Debt | -508 | |||||||||
| Equity Value | 16,536 | |||||||||
| Diluted Shares Outstanding, MM | 50 | |||||||||
| Equity Value Per Share | 332.72 |
What You Will Receive
- Adjustable Forecast Variables: Modify key assumptions (growth %, profit margins, discount rate) to explore various scenarios.
- Comprehensive Data: United Therapeutics Corporation’s financial information pre-loaded to facilitate your analysis.
- Instant DCF Calculations: The template automatically computes Net Present Value (NPV) and intrinsic value for you.
- Tailored and Professional Design: A refined Excel model that meets your specific valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating forecasts, confirming strategies, and enhancing efficiency.
Key Features
- Real-Life UTHR Data: Pre-filled with United Therapeutics Corporation’s historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures as needed.
- Dynamic Valuation Model: Instant updates to Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Testing: Develop various forecast scenarios to evaluate different valuation results.
- User-Friendly Design: Intuitive, organized, and tailored for both professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review United Therapeutics Corporation’s (UTHR) pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions.
Why Choose This Calculator for United Therapeutics Corporation (UTHR)?
- Accuracy: Utilizes real United Therapeutics financial data for precise calculations.
- Flexibility: Allows users to easily adjust and test various inputs.
- Time-Saving: Avoid the complexity of creating a DCF model from the ground up.
- Professional-Grade: Crafted with the precision and usability expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Evaluate United Therapeutics Corporation’s (UTHR) fair value to inform investment choices.
- CFOs: Utilize a high-quality DCF model for accurate financial reporting and analysis.
- Consultants: Easily modify the template for client valuation reports specific to United Therapeutics Corporation (UTHR).
- Entrepreneurs: Discover financial modeling techniques employed by leading biotech firms.
- Educators: Implement it as an educational resource to illustrate valuation strategies.
What the Template Contains
- Pre-Filled DCF Model: United Therapeutics Corporation’s (UTHR) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate United Therapeutics Corporation’s (UTHR) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.